Urinary excretion of liver-type fatty acid-binding protein reflects the severity of sepsis

被引:0
|
作者
Sato E. [1 ]
Kamijo-Ikemori A. [2 ,4 ]
Oikawa T. [3 ]
Okuda A. [3 ]
Sugaya T. [3 ,4 ]
Kimura K. [5 ]
Nakamura T. [1 ,4 ]
Shibagaki Y. [4 ]
机构
[1] Division of Nephrology, Department of Medicine, Shinmatsudo Central General Hospital, 1-380 Shinmatsudo, Matsudo,Chiba
[2] Department of Anatomy, St. Marianna University School of Medicine, Sugao, Miyamae-Ku, Kawasaki,Kanagawa
[3] Cmic Holdings Co. Ltd., Hamamatsucho Bldg., 1-1-1 Shibaura, Minato-ku, Tokyo
[4] Department of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine, Sugao, Miyamae-Ku, Kawasaki, 216-8511, Kanagawa
[5] Department of Internal Medicine, Japan Community Health Care Organization, Tokyo Takanawa Hospital, Tokyo
关键词
AKI; Biomarker; L-FABP; Oxidative stress; POC; Sepsis;
D O I
10.1186/s41100-017-0107-x
中图分类号
学科分类号
摘要
Sepsis due to microbial invasion often causes multiple organ failure (MOF), including acute kidney injury (AKI), with high mortality rates in serious cases. Hence, there is an urgent need for diagnostic biomarkers that can be used to rapidly, accurately, and easily detect sepsis to identify the condition early and guide the selection of appropriate treatment. Liver-type fatty acid-binding protein (L-FABP), which localizes in renal proximal tubules, is excreted into the urine in response to oxidative stress-induced tubular injury. Because of this mechanism, L-FABP has been reported to be a useful urinary biomarker not only for renal disease but also for the severity of sepsis. Based on this concept, we developed a new L-FABP point-of-care (POC) assay kit that can be used to rapidly measure human L-FABP in the urine to further improve the usefulness of this biomarker in clinical settings. In this review, we describe the molecular mechanisms of L-FABP, its clinical usefulness, and the performance of the POC assay kit. © 2017 The Author(s).
引用
收藏
相关论文
共 50 条
  • [1] Renal expression and urinary excretion of liver-type fatty acid-binding protein in cats with renal disease
    Katayama, Masaaki
    Ohata, Keiichi
    Miyazaki, Tamako
    Katayama, Rieko
    Wakamatsu, Nobuko
    Ohno, Misa
    Yamashita, Tetsuro
    Oikawa, Tsuyoshi
    Sugaya, Takeshi
    Miyazaki, Masao
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2020, 34 (02) : 761 - 769
  • [2] Urinary liver-type fatty acid-binding protein in pediatric nephrotic syndrome and tubular dysfunction
    Nishida, Masashi
    Kawakatsu, Hidekazu
    Hamaoka, Kenji
    PEDIATRICS INTERNATIONAL, 2018, 60 (05) : 442 - 445
  • [3] Urinary excretion of liver-type fatty acid-binding protein as a marker of progressive kidney function deterioration in patients with chronic glomerulonephritis
    Mou, Shan
    Wang, Qin
    Li, Jialin
    Shi, Beili
    Ni, Zhaohui
    CLINICA CHIMICA ACTA, 2012, 413 (1-2) : 187 - 191
  • [4] The Role of Urinary Liver-Type Fatty Acid-Binding Protein in Critically Ill Patients
    Cho, Eunjung
    Yang, Ha Na
    Jo, Sang-Kyung
    Cho, Won-Yong
    Kim, Hyoung-Kyu
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2013, 28 (01) : 100 - 105
  • [5] Urinary liver-type fatty acid-binding protein predicts recovery from acute kidney injury
    Wang, Liang
    Xue, Jing
    Chen, Caimei
    Zhang, Zhijian
    Deng, Zhaohong
    Sun, Zhuxing
    Xing, Changying
    CLINICAL NEPHROLOGY, 2015, 84 (05) : 255 - 261
  • [6] Clinical evaluation of urinary liver-type fatty acid-binding protein for the diagnosis of renal diseases in dogs
    Takashima, Satoshi
    Nagamori, Yumiko
    Ohata, Keiichi
    Oikawa, Tsuyoshi
    Sugaya, Takeshi
    Kobatake, Yui
    Nishii, Naohito
    JOURNAL OF VETERINARY MEDICAL SCIENCE, 2021, 83 (09) : 1465 - 1471
  • [7] Distinct Roles of Urinary Liver-Type Fatty Acid-Binding Protein in Non-Diabetic Patients with Anemia
    Imai, Naohiko
    Yasuda, Takashi
    Kamijo-Ikemori, Atsuko
    Shibagaki, Yugo
    Kimura, Kenjiro
    PLOS ONE, 2015, 10 (05):
  • [8] Urinary Excretion of Liver Type Fatty Acid Binding Protein Accurately Reflects the Degree of Tubulointerstitial Damage
    Yokoyama, Takeshi
    Kamijo-Ikemori, Atsuko
    Sugaya, Takeshi
    Hoshino, Seiko
    Yasuda, Takashi
    Kimura, Kenjiro
    AMERICAN JOURNAL OF PATHOLOGY, 2009, 174 (06) : 2096 - 2106
  • [9] Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria
    Nakamura, Tsukasa
    Sugaya, Takeshi
    Kawagoe, Yasuhiro
    Ueda, Yoshihiko
    Koide, Hikaru
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2006, 22 (05) : 385 - 389
  • [10] Urinary liver-type fatty acid-binding protein predicts adverse outcomes in acute kidney injury
    Ferguson, Michael A.
    Vaidya, Vishal S.
    Waikar, Sushrut S.
    Collings, Fitz B.
    Sunderland, Kelsey E.
    Gioules, Costas J.
    Bonventre, Joseph V.
    KIDNEY INTERNATIONAL, 2010, 77 (08) : 708 - 714